- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03352778
IMRT vs 2DRT for NPC Patients
Long Term Results of the Prospective Randomized Study of Intensity-modulated Radiotherapy (IMRT) Versus Two-dimensional Radiotherapy (2DRT) in Early Stage Nasopharyngeal Carcinoma (NPC) Patients
Irradiation of the parotid gland with subsequent long-term xerostomia is a well-recognized complication after radiotherapy for head and neck (HAN) cancers. A number of studies have shown that IMRT could minimize the radiation dose to the parotid glands and hence the risk of developing xerostomia. The benefit of IMRT has also been demonstrated in prior dosimetric and non-randomized studies in NPC patients. In 2007, the investigators have published the prospective randomized study of IMRT versus 2DRT in early stage NPC patients. In the study, IMRT had lower incidence of observer-rated severe xerostomia, higher parotid and whole saliva flow rate, than patients in 2DRT arm at 1 year after treatment. However, there was no significant difference in patient-reported outcome, i.e. subjective xerostomia scoring, between the 2 arms. The underlying reason for the incoherent findings in terms of objective and subjective xerostomia outcome remains uncertain. One of the possible explanations for this observation could be the better parotidsparing with IMRT alone may not entirely sufficient to maintain oral cavity lubrication while the other mucin-secretory salivary gland protection is also essential. Another possible explanation for the insignificant improvement in patient-reported outcome with IMRT is the short follow-up time. Gradual recovery or improvement in various quality of life parameters was not uncommonly seen several years after definitive radiotherapy for HAN cancer patients. There is much interest in studying the long term clinical outcome, especially the treatment-related complications, for the patients who had randomized and treated in the prior presented prospective study.
In this study, the long term results, in particular the xerostomia rating will be assessed and compared in NPC patients who had participated in the prior reported prospective randomized study of IMRT vs 2DRT.
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- The Chinese University of Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The NPC patient, who had been enrolled, randomized and treated in the prior prospective randomized study of IMRT vs 2DRT.
- Regular follow-up for more than five years from the end of study intervention (i.e. IMRT or 2DRT for NPC).
- Patient is able to sign the study-specific informed consent.
- ECOG performance status 0 or 1.
- Patient is able to complete the study's questionnaire.
Exclusion Criteria:
- NPC patients who had not been randomized or allocated to the study intervention, even though had been enrolled in the prior reported study.
- Loss of regular follow-up from the end of study intervention.
- Regular follow-up for less than five years from the end of study intervention.
- Patients with known recurrent or metastatic disease.
- Patients with secondary malignancy occurred after completion of the previous study's treatment (i.e. radiotherapy).
- Active untreated infections
- Major medical or psychiatric illness
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
IMRT
|
66Gy by intensity-modulated radiotherapy
|
2DRT
|
66Gy by 2-dimensional radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure QOL difference between 2DRT vs IMRT by EORTC QLQ-C30 core questionnaire. A 10-point difference of mean scores of QOL between groups were significant.
Time Frame: 2 years
|
2 years
|
To measure QOL difference between 2DRT vs IMRT by EORTC QLQ-H&N 35 questionnaire. A 10-point difference of mean scores of QOL between groups were significant.
Time Frame: 2 years
|
2 years
|
To measure difference in xerostomia score between 2DRT vs IMRT by using the xerostomia questionnaire (6-item xerostomia questionnaire. Johnson et al). A low score indicates worse xerostomia.
Time Frame: 2 years
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the difference of the incidence of loco-regional recurrence between 2DRT vs IMRT.
Time Frame: 2 years
|
2 years
|
To measure the difference of the overall survival and progression-free survival between 2DRT vs IMRT.
Time Frame: 2 years
|
2 years
|
To measure the difference of numbers of 2DRT vs IMRT patients with treatment-related adverse events as assessed by RTOG/EORTC Late Radiation Morbidity Scoring Criteria.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NPC031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NPC
-
National University Hospital, SingaporeOtsuka Pharmaceutical Co., Ltd.Unknown
-
National Taiwan University HospitalUnknownReproducibility and Reliability of Epstein-Barr Virus (EBV) DNA/RNA Measures in Nasopharyngeal SwabsSuspect NPC Patients | NPC Multiplex FamiliesTaiwan
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Chinese University of Hong KongActive, not recruiting
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingRecurrent or Metastatic NPCChina, Taiwan, Singapore
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsUnknown
-
Nanfang Hospital of Southern Medical UniversityRecruitingCisplatin | NPC | CarboplatinChina
-
CCTUActive, not recruiting
-
Taichung Veterans General HospitalCompletedNasopharyngeal Carcinoma | Radiotherapy | EBV | NPCTaiwan
-
Hai-Qiang Mai,MD,PhDZhejiang Cancer Hospital; Fudan University; Cancer Institute and Hospital, Chinese... and other collaboratorsNot yet recruiting
Clinical Trials on IMRT
-
Cancer Institute and Hospital, Chinese Academy...UnknownSmall-cell Lung CancerChina
-
National Cancer Institute, EgyptActive, not recruiting
-
Sun Yat-sen UniversityActive, not recruitingQuality of Life | Mortality | Nasopharyngeal Neoplasms | ComplicationsChina
-
Royal Marsden NHS Foundation TrustCompleted
-
University of Michigan Rogel Cancer CenterTerminatedBreast CancerUnited States
-
Washington University School of MedicineTerminatedHead and Neck CancerUnited States
-
Alberta Health servicesCompleted
-
Jiangsu Cancer Institute & HospitalNot yet recruitingStage IVA Nasopharyngeal CarcinomaChina
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedSexual Dysfunction | Prostate Cancer | Radiation Toxicity | Psychosocial Effects of Cancer and Its TreatmentUnited States, Canada
-
St. Jude Children's Research HospitalMayo ClinicTerminatedAbdominal NeuroblastomaUnited States